Viewing nowLaniten Tablet 125mg (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Hankook HyuTex Pharmaceutical Co., Ltd.

MFDS item code 201901480 · Approved 2019.03.11 · Insurance code 649104300
Treatment of onychomycosis and fungal skin infections (such as tinea pedis and tinea cruris), and tinea capitis
This medication is used to treat tinea pedis, tinea corporis, tinea cruris, onychomycosis in adults, and tinea capitis in children, caused by dermatophytes.
Administer terbinafine 125 mg per dose twice daily or 250 mg per dose once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. A treatment duration of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. Reduce the daily dose by 1/2 in patients with creatinine clearance below 50 mL per minute.
Administer to children aged 2 years or older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment should be administered regularly for the appropriate prescribed duration. Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Experience with administration is limited; therefore, the decision to treat should be based on consideration of the benefits and risks. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.
This medication is not recommended for patients with chronic liver disease or active liver disease. Liver function status must be checked prior to administration, and regular liver function tests should be performed during treatment. If liver function deteriorates, discontinue medication immediately, and inform a doctor if symptoms such as nausea, loss of appetite, fatigue, vomiting, abdominal pain, or jaundice occur. This medication should not be administered to individuals with blood disorders, severe renal failure, children under 2 years old, nursing mothers, and patients with certain genetic disorders. Use with caution in the elderly, patients with impaired renal function, and underweight children; if severe skin rash or allergic reactions occur, discontinue immediately. This medication can cause side effects affecting the liver, blood, skin, musculoskeletal system, gastrointestinal tract, and nervous system; consult a physician if any unusual symptoms arise. Symptoms such as dizziness may occur when driving or operating machinery, so caution is necessary. Potential interactions with other medications may occur, so inform your doctor or pharmacist of any other medications being taken, as dosage adjustments may be necessary. Women who are pregnant or may become pregnant should use this medication cautiously, and nursing mothers should discontinue breastfeeding. Overdosage may result in symptoms such as headache, nausea, abdominal pain, dizziness, and appropriate medical attention should be sought immediately. This medication should be stored out of reach of children, protected from direct sunlight, and kept at room temperature.
Liver failure, hepatitis, cholestasis, jaundice, rash, pruritus, fever, nausea, vomiting, loss of appetite, malaise, γ-GTP elevation, AST/ALT elevation, LDH elevation, ALP elevation, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriatic rash, exacerbation of psoriasis, hair loss, musculoskeletal reaction, arthralgia, myalgia, weakness, CPK elevation, serum myoglobin elevation, urinary myoglobin elevation, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, gastric discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, loss of taste, taste disorder, dizziness, drowsiness, sensory disturbances, sensory loss, decreased attention, insomnia, BUN elevation, polyuria, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol in the blood, elevated triglyceride levels, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, vision loss, hearing loss, auditory impairment, vasculitis, permanent anosmia, hyposmia, eosinophilia, drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase activity, headache, nausea, upper abdominal pain, dizziness
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. Additionally, it is recommended to store the medication at a cool room temperature, specifically between 1 to 30 degrees Celsius.
White round tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Hankook HyuTex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.